课题基金 / 基金详情

CHLORHEXIDINE IRRIGATION TO PREVENT INFECTION

CHLORHEXIDINE IRRIGATION TO PREVENT INFECTION
氯己定冲洗以预防感染
批准号:
2761839
负责人:
DWIGHT J ROUSE
金额:
$18.16万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-01-01 至 2001-12-31

项目摘要

项目成果

DWIGHT J ROUSE的其他基金

相似基金

相关文献

中文摘要
翻译
临床上明显的胎盘、胎膜或子宫感染 分娩期间(绒毛膜羊膜炎)的并发症占妊娠总数的1%到11%。 产后子宫感染(子宫内膜炎)的发生率各不相同。 从阴道分娩后的1%-3%下降到剖宫产后的15%-20%。 绒毛膜羊膜炎是公认的菌血症和败血症的危险因素 休克,并与几倍增加的风险有关 剖腹产。在以下情况下进行剖腹产的妇女 绒毛膜羊膜炎增加了严重盆腔和伤口的风险 感染。子宫内膜炎最严重的并发症(包括, 通常发生在剖宫产后。 绒毛膜羊膜炎和子宫内膜炎的经济成本(统称为 称为围产期感染)是实质性的,并可能 保守估计,在美国,邮编每年约为1.2亿美元 单单是剖腹产感染。绒毛膜羊膜炎妇女的后代 接受侵入性诊断测试(例如,腰椎穿刺术 脑脊液评估),静脉抗生素治疗,延长 住院、败血症和死亡,幸存者面临着更高的风险 脑性瘫痪。此外,照顾婴儿出生的成本 患有绒毛膜羊膜炎的母亲可能很容易超过母亲的费用 产周感染。因为绒毛膜氨基炎的病原学和 子宫内膜炎是内源性宫颈阴道的上行性感染 细菌,在产程中用抗菌药物冲洗阴道和宫颈 细菌是预防围产期感染的合理方法。至 要在临床上有用,这样的药物需要拥有广泛的 抗菌活性,对母婴无毒、无刺激性 胎儿。理想情况下,该代理应该是商业上可获得的,而且价格低廉。 广泛使用的医用消毒剂洗必泰满足了这些要求 要求。在那里,我们的目标是:1)进行安慰剂对照的双重- 随机临床试验,以确定产程中阴道 用稀释的洗必泰溶液冲洗将防止或减轻 产程中用稀释剂阴道冲洗的试验 洗必泰溶液可预防或减轻母体的严重程度 围产期感染--绒毛膜羊膜炎和子宫内膜炎;2)确定 是否在产程中用稀释洗必泰阴道冲洗 溶液会降低绒毛膜的微生物侵袭率; 3)确定产程中是否用稀释液冲洗阴道 洗必泰溶液可降低急性组织学发生率 绒毛膜羊膜炎;4)确定是否有细菌存在 阴道病与洗必泰的不同作用有关 阴道冲洗对产妇围产期感染率的影响 确定产程中是否用稀释液冲洗阴道 洗必泰溶液可降低新生儿败血症发生率。
英文摘要
Clinically overt infection of the placenta, fetal membranes, or uterus during labor (chorioamnionitis) complicates from 1% to 11% of pregnancies. The incidence of uterine infection after delivery (endometritis) varies from 1%-3% after vaginal delivery to 15-20% after cesarean delivery. Chorioamnionitis is a recognized risk factor for bacteremia and septic shock and is associated with a several-fold increase in the risk for cesarean delivery. Women who undergo cesarean delivery in the setting of chorioamnionitis are at increased risk of serious pelvic and wound infection. The most severe complications of endometritis (including, rarely, death from whelming sepsis) usually occur after cesarean delivery. The economic costs of chorioamnionitis and endometritis (collectively referred to as peripartal infection) are substantial and can be conservatively estimated at $120,000,000 a year in the U.S. for post- cesarean infections alone. The offspring of women with chorioamnionitis are exposed to invasive diagnostic testing (e.g. lumbar puncture for cerebrospinal fluid assessment), intravenous antibiotic therapy, prolonged hospitalization, sepsis, and death, Survivors face an increased risk of cerebral palsy. Furthermore, the costs of caring for infants born to mothers with chorioamnionitis may easily exceed the maternal costs of peripartal infection. Because the etiology of chorioaminonitis and endometritis is ascending infection of endogenous cervico-vaginal bacteria, intrapartum irrigation of the vagina and cervix with an anti- bacterial as a logical approach to prevention of peripartal infection. To be clinically useful, such an agent would need to possess broad antimicrobial activity, and be non-toxic and non-irritating for mother and fetus. Ideally the agent would be commercially available and inexpensive. The widely used medical disinfectant chlorhexidine satisfies these requirements. There we aim: 1) To conduct a placebo-controlled, double- masked, randomized clinical trial to determine whether intrapartum vaginal irrigation with a dilute chlorhexidine solution will prevent or lessen the trial to determine whether intrapartum vaginal irrigation with a dilute chlorhexidine solution will prevent or lessen the severity of the maternal peripartal infections--chorioamnionitis and endometritis; 2) To determine whether intrapartum vaginal irrigation with a dilute chlorhexidine solution will reduce the rate of microbial invasion of the chorioamnion; 3) To determine whether intrapartum vaginal irrigation with a dilute chlorhexidine solution will reduce the rate of acute histologic chorioamnionitis; 4) To determine whether the presence of bacterial vaginosis is associated with a differential effect of chlorhexidine vaginal irrigation on the maternal peripartal infection rate; and 5) To determine whether intrapartum vaginal irrigation with a dilute chlorhexidine solution reduces the rates of neonatal sepsis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Brown/WIH Eunice Kennedy Shriver NICHD MFM Units Network Site
Brown/WIH Eunice Kennedy Shriver NICHD MFM Units Network Site
Eunice Kennedy Shriver NICHD Maternal-Fetal Medicine Units (MFMU) Network
NICHD Maternal Fetal Medicine Units Network
海外基金